Selexis SUREtechnology Platform – The Formula 1 Race Car of Cell Line Development

Written by Robert Meister on July 31, 2018

In building a marketing campaign for our lead technology, we wanted something that would reflect and represent the continued innovation and power of our SUREtechnology Platform™ with images and representations that would capture attention and compel biopharmaceutical decision makers to learn more about us. As we know, standing out in the crowd is hard work. […]

Read More

Best-in-Class Cell Line Development and Biologic Manufacturing Coming Together

Written by Robert Meister on July 17, 2018

Selexis CEO Igor Fisch, PhD, and KBI Biopharma President and CEO Tim Kelly, PhD, address the most common questions about being a part of JSR Life Sciences and their new collaboration, GENE to GMP in 9 Months

Read More

Selexis: It’s a Great Place to Work®

Written by Igor Fisch, PhD on May 17, 2018

The important thing is not to stop questioning. Curiosity has its own reason for existing. – Albert Einstein As an entrepreneur, I know firsthand how thrilling it is to start a new company. We aim for success, and we determine for ourselves what that success will look like. Maybe it’s increased sales growth; maybe it’s attracting […]

Read More

Selexis Achieves 100th Commercial License Agreement

Written by Igor Fisch, PhD on May 2, 2018

In 2001, I co-founded Selexis with prize money that I won from the de Vigier Foundation in Switzerland followed by the NETS prize (the predecessor program of Venture Kick), a philanthropic three-stage funding model initiated to support Swiss startups. Fast forward to 2018, Selexis is now among the top mammalian cell line development companies worldwide […]

Read More

Knowledge Is Power for Today’s CEOs – Keeping Up With Industry News

Written by Igor Fisch, PhD on February 22, 2018

As a young scientist and entrepreneur, I understood early in my career just how important it is to stay ahead of the curve. Being a voracious consumer of information and news was the best way to see the big picture, evaluate trends and market drivers, and gain the knowledge that empowered my strategic vision. Today, […]

Read More

Using CHO “Omics” to Address Production of Increasingly Complex Biotherapeutics

Written by Guest Blogger Pierre-Alain Girod, PhD on February 1, 2018

Increasingly, solutions for complex human diseases are being addressed with increasingly complex protein therapeutic modalities. These include molecules such as bi-specific proteins, DARPins, triabodies and novel scaffolds decorated with peptides, enzymes or growth factors, to name a few. Many, if not most, of these proteins do not exist in nature and producing them presents a […]

Read More

2017: Year in Review

Written by Igor Fisch, PhD on January 4, 2018

An idea is something that won’t work unless you do. – Thomas Edison As I look around our new corporate headquarters and laboratories, I am reminded of how far Selexis has come since we began our work in cell line generation more than 15 years ago. 2017 was certainly no exception and I’m so proud […]

Read More

Biosimilarity: It starts by selecting the right manufacturing cell line

Written by Igor Fisch, PhD on December 21, 2017

The recombinant therapeutic patent cliff has ushered in a new promise for access to less expensive biologic therapies, called biosimilars. Just recently, in fact, the US Food & Drug Administration approved the first biosimilar for the treatment of certain breast and stomach cancers, known as Ogivri (trastuzumab-dkst) – which is a biosimilar to Herceptin (trastuzumab). […]

Read More

CHO Cells Are Here to Stay?

Written by Igor Fisch, PhD on November 30, 2017

I have recently read a couple of industry articles around cell line development that claim the Chinese hamster ovary (CHO) cell line is not the future of biomanufacturing and that alternative non-mammalian platforms, such as fungal, algae and plant systems, will offer the low-cost solutions that CHO cannot. Make no mistake, it will be a […]

Read More